KR20230032526A - Composition for inhibiting eye damage - Google Patents

Abstract

A composition for inhibiting eye damage is disclosed in the present specification. In one aspect, 2-isopropylmalic acid, a salt, hydrate or solvate thereof, which is an active ingredient of the present disclosure, can activate primary cilia of the eye to suppress eye damage caused by fine dust or the like. In addition, in one aspect, 2-isopropylmalic acid, the salt, hydrate or solvate thereof, which is the active ingredient of the present disclosure, is a safe material and has an advantage in that it can be treated in various forms such as cosmetics and foods.

Description

Composition for inhibiting eye damage {COMPOSITION FOR INHIBITING EYE DAMAGE}

The present specification relates to a composition for inhibiting eye damage.

The eye is a sensory organ that produces visual information in response to light. The eye is a round ball with an interior space surrounded by three membranes. The outermost membrane is the transparent cornea and the opaque sclera. The choroid, in the middle, carries blood vessels that supply nutrients. The innermost membrane is the retina. The ciliary body and the iris are covered with the ciliary epithelium and the iris epithelium, which are connected to the retina.

It is known that diseases such as retinitis pigmentosa, age-related macular degeneration, and diabetic retinopathy are induced when damage to the eyes, especially retinal cells, is caused by stimuli such as ultraviolet rays and fine dust, but there are few solutions to control them. .

Primary cilia are cell structures that play an important role in helping cells behave in response to changes in the surrounding environment as bioantennas. When these primary cilia are activated in retinal cells, it is known to have desirable effects on the eyes, such as activating retinal development and protecting rod cells and cone cells.

The present inventors confirmed that 2-isopropylmalic acid has an effect of inhibiting eye damage by activating primary cilia and completed the present invention.

Korean Patent Publication No. 10-2014-0069908

In one aspect, the present disclosure seeks to provide a composition for inhibiting eye damage.

In one aspect, the present disclosure provides a composition for inhibiting eye damage comprising 2-isopropylmalic acid, a salt, hydrate or solvate thereof as an active ingredient.

In an exemplary embodiment, the composition of 2-isopropylmalic acid, a salt, hydrate or solvate thereof may be administered at a dosage of 1.7 to 90 mg/kg/day.

In one exemplary embodiment, the eye damage may be damage to retinal cells.

In an exemplary embodiment, the retinal cells may include retinal pigment epithelial cells.

In one exemplary embodiment, the eye damage may be caused by fine dust.

In an exemplary embodiment, the composition may be a food, pharmaceutical or cosmetic composition.

In one aspect, the present disclosure provides a composition for activating primary cilia of the eye comprising 2-isopropylmalic acid, a salt, hydrate or solvate thereof as an active ingredient.

In an exemplary embodiment, the activation of primary cilia of the eye may be activation of primary cilia suppressed by fine dust.

In an exemplary embodiment, the primary cilia may be primary cilia of retinal cells.

In an exemplary embodiment, the composition may be a food composition, a cosmetic composition or a pharmaceutical composition.

In one aspect, the composition according to the present disclosure has an excellent effect of inhibiting eye damage without side effects.

In one aspect, the composition according to the present disclosure is excellent in relieving eye inflammation.

In one aspect, a composition according to the present disclosure is capable of activating the primary cilia of the eye.

1 is a result of measuring the cytotoxicity of 2-isopropylmalic acid according to an embodiment of the present disclosure.
2 is a result of treating retinal pigment epithelial cells with 2-isopropylmalic acid according to an embodiment of the present disclosure and observing them under a flashlight microscope.
3 is a graph showing the results obtained by treating retinal pigment epithelial cells with 2-isopropylmalic acid according to an embodiment of the present disclosure and measuring the primary cilia generation rate and primary cilia length.
4 is a result of treating retinal pigment epithelial cells exposed to fine dust with 2-isopropylmalic acid according to an embodiment of the present disclosure and observing them under a flashlight microscope.
5 is a graph showing the results obtained by treating retinal pigment epithelial cells exposed to fine dust with 2-isopropylmalic acid according to an embodiment of the present disclosure, and measuring the primary cilia generation rate and primary cilia length.
6 is a result of measuring the c-Jun phosphorylation inhibitory effect of 2-isopropylmalic acid according to an embodiment of the present disclosure.
7 and 8 are results of measuring the intracellular reactive oxygen species inhibitory effect of 2-isopropylmalic acid according to one embodiment of the present disclosure.
9 is a result of measuring the inflammatory cytokine inhibitory effect of 2-isopropylmalic acid according to one embodiment of the present disclosure.

Hereinafter, the present invention will be described in detail.

In one aspect, the present disclosure provides a composition for inhibiting eye damage comprising 2-isopropylmalic acid, a salt, hydrate or solvate thereof as an active ingredient.

In the present specification, 2-isopropylmalic acid may be represented by Formula 1 below.

[Formula 1]

As used herein, "salt" means a salt according to one aspect of the present invention that is acceptable in medicine, cosmetics, and food and has the desired activity of the parent compound. These salts are (1) formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like; or acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl) Benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-Toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2,2,2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tert - acid addition salts formed with organic acids such as butylacetic acid, laurylsulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, and muconic acid; or (2) a salt formed when an acidic proton present in the parent compound is substituted. In addition, the salt may be a pharmaceutically acceptable salt.

As used herein, “pharmaceutically acceptable” means approval by the government or a regulatory body equivalent thereto that can be used in animals, more specifically in humans, by avoiding significant toxic effects when used in normal medical dosages. Received or approved, or listed in a pharmacopeia or otherwise recognized in a general pharmacopeia.

In the present specification, "hydrate" means a compound in which water is bound, and is a broad concept including an inclusion compound having no chemical bonding force between water and the compound.

As used herein, "solvate" refers to a higher order compound formed between solute molecules or ions and solvent molecules or ions.

In the present specification, "active ingredient" means a component that exhibits the desired activity alone or that can exhibit activity together with a carrier that has no activity by itself.

In one embodiment, 2-isopropylmalic acid, a salt, hydrate or solvate thereof by administration of the composition may be administered at a dosage of 1.7 to 90 mg/kg/day. When the dosage of 2-isopropylmalic acid, its salt, hydrate or solvate by administration of the composition is less than 1.7 mg/kg/day, it may be difficult to show the effect of inhibiting eye damage, and it is more than 90 mg/kg/day If it is, it can stimulate. Specifically, the dosage of 2-isopropylmalic acid, its salt, hydrate or solvate by administration of the composition is 1.7 mg/kg/day or more, 2 mg/kg/day or more, 2.5 mg/kg/day or more, 3 mg/kg/day or more, 3.5 mg/kg/day or more, 4 mg/kg/day or more, 4.5 mg/kg/day or more, 5 mg/kg/day or more, 5.5 mg/kg/day or more, 6 mg /kg/day or more, 6.5 mg/kg/day or more, 7 mg/kg/day or more, 7.5 mg/kg/day or more, 8 mg/kg/day or more, 8.5 mg/kg/day or more, 9 mg/kg /day or more, 9.5 mg/kg/day or more, 10 mg/kg/day or more, 10.5 mg/kg/day or more, 11 mg/kg/day or more, 11.5 mg/kg/day or more, 12 mg/kg/day 12.5 mg/kg/day or more, 13 mg/kg/day or more, 14 mg/kg/day or more, 15 mg/kg/day or more, 16 mg/kg/day or more, 17 mg/kg/day or more; 18 mg/kg/day or more, 19 mg/kg/day or more, 20 mg/kg/day or more, 21 mg/kg/day or more, 22 mg/kg/day or more, 23 mg/kg/day or more, 24 mg /kg/day or more or 25 mg/kg/day or more, but less than or equal to 90 mg/kg/day, less than or equal to 89 mg/kg/day, less than or equal to 88 mg/kg/day, less than or equal to 87 mg/kg/day, or less than or equal to 86 mg/kg/day kg/day or less, 85 mg/kg/day or less, 84 mg/kg/day or less, 83 mg/kg/day or less, 82 mg/kg/day or less, 81 mg/kg/day or less, 80 mg/kg/day or less days or less, 79 mg/kg/day or less, 78 mg/kg/day or less, 77 mg/kg/day or less, 76 mg/kg/day or less, 75 mg/kg/day or less, 74 mg/kg/day or less , 73 mg/kg/day or less, 72 mg/kg/day or less, 71 mg/kg/day or less, 70 mg/kg/day or less, 69 mg/kg/day or less, 68 mg/kg/day or less, 67 Not more than mg/kg/day, not more than 66 mg/kg/day or not more than 65 mg/kg/day can

In one embodiment, the eye damage may be damage to retinal cells. The retinal cells may include retinal pigment epithelial cells.

In one embodiment, the eye damage may be caused by fine dust.

In one embodiment, inhibiting eye damage may include relieving eye inflammation.

In one embodiment, the composition is capable of activating primary cilia. In the present specification, activating primary cilia may mean promoting the production of primary cilia in a cell or increasing the length of primary cilia.

In the present specification, "primary cilia" are organelles protruding from the cell body, which sense various external stimuli including chemical stimuli, physical stimuli, light, osmotic pressure, fluid flow, and gravitational signals. When the activity of primary cilia of the eye is inhibited, retinitis pigmentosa, age-related macular degeneration, diabetic retinopathy, inflammatory eye diseases, and the like can be induced.

In one embodiment, the composition can increase the production of primary cilia of the eye, which is suppressed by fine dust.

In this specification, "fine dust" refers to particulate matter that floats or scatters in the air for a long time as a very small substance invisible to our eyes. Specifically, the particle size of the fine dust may have a particle diameter of 10 μm or less (PM 10), more specifically, 2.5 μm or less (PM 2.5). In particular, particulate matter having a particle diameter of 2.5 μm or less (PM 2.5) is referred to as “ultrafine dust”, and in this specification, “fine dust” is intended to include “ultrafine dust”.

In one embodiment, the composition may be a cosmetic composition. The cosmetic composition, for example, softening lotion, astringent lotion, nutrient lotion, nutrient cream, massage cream, eye cream, eye essence, essence, cleansing cream, cleansing lotion, cleansing foam, cleansing water, pack, powder, body lotion , Body cream, body essence, body cleanser, hair dye, shampoo, rinse, hair styling agent, hair growth agent, ointment, gel, cream, patch, spray, powder, and skin adhesive type, but may have formulations such as, but are not limited thereto.

In addition, other ingredients in addition to the essential ingredients described above in each formulation can be appropriately selected and blended without difficulty by those skilled in the art according to the type or purpose of use of other external preparations.

The cosmetic composition may be provided in any formulation suitable for topical application. For example, it may be provided in the form of a solution, an emulsion obtained by dispersing an oil phase in an aqueous phase, an emulsion obtained by dispersing an aqueous phase in an oil phase, a suspension, a solid, a gel, a powder, a paste, a microneedle, a foam, or an aerosol composition. there is. Compositions of such formulations may be prepared according to conventional methods in the art.

The cosmetic composition according to the present specification may further include functional additives and components included in general cosmetic compositions in addition to the compounds of the present specification. The functional additive may include a component selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, high-molecular peptides, high-molecular polysaccharides, sphingolipids, and seaweed extracts. The cosmetic composition according to the present specification may include other components capable of giving a synergistic effect to the main effect within a range that does not impair the main effect. In addition, the cosmetic composition according to the present specification may further include a moisturizer, an emollient agent, a surfactant, a UV absorber, a preservative, a bactericide, an antioxidant, a pH adjuster, an organic and inorganic pigment, a fragrance, a cooling agent or an antiperspirant. The blending amount of the components can be easily selected by those skilled in the art within a range that does not impair the purpose and effect of the present specification, and the blending amount may be 0.001 to 10% by weight, specifically 0.01 to 3% by weight based on the total weight of the composition. there is.

In one embodiment, the composition may be a food composition. The formulation of the food composition is not particularly limited, but may be formulated into, for example, tablets, granules, pills, powders, liquids such as drinks, caramels, gels, bars, tea bags, and the like. The food composition of each formulation can be selected and blended without difficulty by those skilled in the art according to the formulation or purpose of use other than the active ingredient, and synergistic effects can occur when applied simultaneously with other ingredients.

The food composition according to one embodiment includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and enhancers (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, and the like. In addition, the food compositions according to one embodiment may include natural fruit juice, fruit juice beverages, and fruit flesh for preparing vegetable beverages. These components may be used independently or in combination. The ratio of these additives is not so critical, but is generally included in the range of 0 to about 50 parts by weight per 100 parts by weight of the composition according to one embodiment.

In one embodiment, the composition may be a pharmaceutical composition. The pharmaceutical composition may be a composition for preventing or treating retinitis pigmentosa, age-related macular degeneration, diabetic retinopathy or inflammatory eye disease. The pharmaceutical composition may be administered orally, parenterally, rectally, topically, transdermally, intravenously, intramuscularly, intraperitoneally, or subcutaneously. Formulations for oral administration may be tablets, pills, soft and hard capsules, granules, powders, fine granules, solutions, emulsions, or pellets, but are limited thereto. It is not. Formulations for parenteral administration may be solutions, suspensions, emulsions, gels, injections, drops, suppositories, patches or sprays, but are not limited thereto. The formulation can be easily prepared according to a conventional method in the art, and includes surfactants, excipients, wetting agents, emulsification accelerators, suspending agents, salts or buffers for osmotic pressure control, coloring agents, spices, stabilizers, preservatives, preservatives, or Other commonly used adjuvants may be further included.

In another aspect, the present disclosure provides a composition for activating primary cilia of the eye comprising 2-isopropylmalic acid, a salt, hydrate or solvate thereof as an active ingredient.

In one embodiment, the activation of primary cilia of the eye may be activation of primary cilia suppressed by fine dust. When the eye is exposed to fine dust, the production of primary cilia in the eye is suppressed and the length is reduced. The composition according to the present disclosure prevents the suppression of primary cilia by fine dust, enhances the production of primary cilia in the eye, and increases the length of primary cilia in the eye exposed to fine dust.

In one embodiment, the primary cilia of the eye may be primary cilia of retinal cells.

Hereinafter, the present invention will be described in more detail through examples and the like. These examples are only for illustrating the present invention, and it will be apparent to those skilled in the art that the scope of the present invention is not to be construed as being limited by these examples.

[Experimental Example 1] Measurement of cytotoxicity

Human retinal pigmented epithelial (RPE) cells were placed in Dulbecco's Modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS) and cultured at 37°C under 5% CO ₂ conditions. The cultured retinal pigment epithelial cells were treated with 2-isopropylmalic acid at each concentration for 24 hours. CCK8 reagent (Donjindo Co., CK04) was diluted 1/10 in DMEM medium, treated for 3 hours, and then absorbance was measured at 450 nm, and the results are shown in FIG. 1 .

[Experimental Example 2] Primary cilia activation evaluation

To confirm the primary cilia activation effect of 2-isopropylmalic acid, human telomerase-immortalized retinal pigmented epithelial (RPE) cells (ATCC) were inoculated with Smo-GFP plasmid ( Addgene Co.) to prepare RPE/Smo-GFP. RPE/Smo-GFP was treated with 2-isopropylmalic acid (Sigma Aldrich) at different concentrations (20 μM, 100 μM) for 24 hours, and then primary cilia were observed under a confocal microscope (LSM510; Carl Zeiss Microimaging Inc., Thornwood, NY). The production rate and length of primary cilia were measured and the results are shown in FIGS. 2 and 3 . The production rate of primary cilia was expressed as a percentage of the number of cells having primary cilia in the total number of cells, and the length of primary cilia was a measure of the actual length of all cilia observed under a microscope. As a positive control, SAG (SMO agonist, Calbiochem Co.), a primary cilia production promoting substance, was used.

White arrows in FIG. 2 indicate primary cilia, and as can be seen in FIGS. 2 and 3, when 2-isopropylmalic acid (2-IMPA) was treated, the percentage of cells with primary cilia was statistically significant compared to the control group. It was confirmed that the length of the cilia was also increased.

[Experimental Example 3] Evaluation of activation of primary cilia suppressed by fine dust

RPE/Smo-GFP of Experimental Example 2 was treated with fine dust (PM2.5). Specifically, fine dust is directly collected from the air (37.34°N, 127.27°E, 167 m above sea level) using a Teflon filter (Zefluor, Pall Life Science, Ann Arbor, MI, USA) And this was treated with a concentration of 50 ug / ml in the cell culture medium. Then, after treatment with 100 μM of 2-isopropylmalic acid for 24 hours, the fluorescence of Smo-GFP was observed with the naked eye using a fluorescence microscope, and then the primary cilia generation rate and the length of primary cilia were measured, and the results are shown in FIGS. 4 and 5 shown in The production rate of primary cilia was expressed as a percentage of the number of cells having primary cilia in the total number of cells, and the length of primary cilia was a measure of the actual length of all cilia observed under a microscope. As a positive control, SAG (SMO agonist, Calbiochem Co.), a primary cilia production promoting substance, was used.

As can be seen in FIGS. 4 and 5, when fine dust is treated, primary cilia production of retinal pigment epithelial cells is suppressed, but when 2-isopropylmalic acid is treated, the production of primary cilia suppressed by fine dust is restored and the primary cilia are suppressed. It was confirmed that the length of the cilia was also increased.

[Experimental Example 4] Evaluation of biomarker expression change

Evaluation of c-Jun phosphorylation

RPE/Smo-GFP of Experimental Example 2 was treated with fine dust (PM2.5). Then, after treatment with 100 μM of 2-isopropylmalic acid for 24 hours, cell lysate was made, protein was quantified, and the same amount of protein was separated by electrophoresis, and then c-Jun, p-c-Jun (phosphorylated c-Jun ) The expression of each protein was measured by an antigen-antibody reaction using an antibody specific for ), and the results are shown in FIG. 6 .

As can be seen in FIG. 6, when fine dust is treated, phosphorylation of c-Jun is promoted and the amount of p-c-Jun is increased, but when 2-isopropylmalic acid is treated, phosphorylation of c-Jun by fine dust is inhibited. was able to confirm that This effect was similar to SP600125 (Sigma Aldrich), a substance known to inhibit c-Jun phosphorylation. When the phosphorylation of c-Jun is promoted, the production of primary cilia is inhibited. It was found that 2-isopropylmalic acid inhibits phosphorylation of c-Jun to activate primary cilia.

Assessment of intracellular reactive oxygen species (ROS) levels

Intracellular reactive oxygen species (ROS) levels were measured using a fluorescent dye, 2',7'-dichlorofluorescein diacetate (H2DCF-DA) (Invitrogen). H2DCF-DA is a substance that becomes fluorescent by being oxidized to 2',7'-dichlorofluorescein (DCF) by active oxygen. After fine dust (PM2.5) was treated with RPE/Smo-GFP of Experimental Example 2, 100 μM of 2-isopropylmalic acid was treated for 24 hours. Thereafter, incubation with H2DCF-DA (20 M) for 40 minutes in a serum-free medium is shown in FIG. 7 for fluorescence change, and the relative ratio compared to the control group is shown in FIG. As a comparison group, the antioxidant N-acetyl-cysteine (NAC) was used.

As can be seen in Figures 7 and 8, it was confirmed that the generation of reactive oxygen species in the retinal pigment epithelial cells increased when fine dust was treated, but the generation of reactive oxygen species was suppressed when 2-isopropylmalic acid was treated.

Assessment of cytokine expression

After fine dust (PM2.5) was treated with RPE/Smo-GFP of Experimental Example 2, 100 μM of 2-isopropylmalic acid was treated for 24 hours. Thereafter, the levels of IL-6 and TNF-α in the cell culture supernatant were measured using an ELISA kit (BD biosciences), and the results are shown in FIG. 9 . The control group was treated with siRNA of IFT88, a major constituent protein forming the structure of primary cilia.

As can be seen in Figure 9, when fine dust is treated, the inflammatory factors IL-6 and TNF-α are increased, but when 2-isopropylmalic acid is treated, it can be seen that the expression of IL-6 and TNF-α is suppressed. there was.

[Formulation Example 1] Liquid Ampoule

According to the composition shown in Table 1 below, liquid ampoules were prepared by a conventional method.

ingredient Content (% by weight) 2-isopropylmalic acid 3.2 arginine 0.50 green tea polyphenols 0.05 indigestible maltodextrin 1.00 vitamin C 0.10 citric acid 0.10 Spices 0.05 Purified water balance Sum 100.00

[Formulation Example 2] Soap

Soap was prepared by a conventional method according to the composition shown in Table 2 below.

ingredient Content (% by weight) 2-isopropylmalic acid 3.00 titanium dioxide 0.20 polyethylene glycol 0.80 glycerin 0.50 Ethylenediaminetetraacetic acid 0.05 salt 1.00 pigment 0.20 soap scent 0.20 soap base balance Sum 100.00

[Formulation Example 3] Lotion

A lotion was prepared by a conventional method according to the composition shown in Table 3 below.

ingredient Content (% by weight) 2-isopropylmalic acid 3.00 L-ascorbic acid-2-phosphate magnesium salt 1.00 Collagen 1.00 sodium citrate 0.10 citric acid 0.05 licorice extract 0.20 1,3-butylene glycol 3.00 Purified water balance Sum 100.00

[Formulation Example 4] Cream

Cream was prepared in a conventional manner according to the composition shown in Table 4 below.

ingredient Content (% by weight) 2-isopropylmalic acid 3.00 Polyethylene glycol monostearate 2.00 Self-emulsifying monostearate glycerin 5.00 cetyl alcohol 4.00 squalene 6.00 Glyceryl tri-2-ethylhenate 6.00 sphingoglycolipids 1.00 1,3-butylene glycol 7.00 Purified water balance Sum 100.00

[Formulation Example 5] Pack

A pack was prepared in a conventional manner according to the composition shown in Table 5 below.

ingredient Content (% by weight) 2-isopropylmalic acid 3.00 polyvinyl alcohol 13.00 L-ascorbic acid-2-phosphate magnesium salt 1.00 lauroylhydroxyproline 1.00 Collagen 2.00 1,3-butylene glycol 3.00 ethanol 5.00 Purified water balance Sum 100.00

[Formulation Example 6] Beauty liquid formulation

According to the composition shown in Table 6 below, a cosmetic liquid formulation was prepared by a conventional method.

ingredient Content (% by weight) 2-isopropylmalic acid 3.00 Hydroxyethylene Cellulose 12.00 xanthan gum 2.00 1,3-butylene glycol 6.00 glycerin 4.00 sodium hyaluronate 5.00 Purified water balance Sum 100.00

[Formulation Example 7] Soft capsule preparation

100 mg of 2-isopropylmalic acid, 160 mg of L-carnitine, 320 mg of soybean oil, 2 mg of palm oil, 8 mg of hydrogenated vegetable oil, 4 mg of yellow wax, and 6 mg of lecithin were mixed and filled into 1 capsule according to a conventional method to prepare a soft capsule.

[Formulation Example 8] Tablets

100 mg of 2-isopropylmalic acid, 500 mg of galacto-oligosaccharide, 80 mg of lactose, and 220 mg of maltose were mixed and granulated using a fluidized bed dryer, and then 6 mg of sugar ester was added and tableted with a tableting machine to prepare tablets.

[Formulation Example 9] Granules

100 mg of 2-isopropylmalic acid, 250 mg of anhydrous crystalline glucose, and 550 mg of starch were mixed, molded into granules using a fluid bed granulator, and filled into bags to prepare granules.

[Formulation Example 10] Drinking agent

After mixing 80 mg of 2-isopropylmalic acid, 10 g of glucose, 0.6 g of citric acid, and 25 g of liquid oligosaccharide, 500 ml of purified water was added and each bottle was filled with 200 ml. After filling the bottle, it was sterilized at 130 ° C. for 4 to 5 seconds to prepare a drink beverage.

Claims (15)

A composition for inhibiting eye damage comprising 2-isopropylmalic acid, a salt, hydrate or solvate thereof as an active ingredient. According to claim 1,
Wherein the 2-isopropylmalic acid (2-isopropylmalic acid), a salt, hydrate or solvate thereof is administered at a dosage of 1.7 to 90 mg/kg/day. According to claim 1,
Wherein the eye damage is damage to retinal cells. According to claim 3,
The retinal cells are composed of retinal pigment epithelial cells. According to claim 1,
The eye damage is a composition that is caused by fine dust. According to any one of claims 1 to 5,
The composition is a food composition composition. According to any one of claims 1 to 5,
Wherein the composition is a pharmaceutical composition. According to any one of claims 1 to 5,
The composition is a cosmetic composition composition. A composition for activating primary cilia of the eye comprising 2-isopropylmalic acid, a salt, hydrate or solvate thereof as an active ingredient. According to claim 9,
The primary cilia activation of the eye is a composition in which the activation of primary cilia suppressed by fine dust. According to claim 9,
Wherein the primary cilia are primary cilia of retinal cells. According to claim 9,
Wherein the 2-isopropylmalic acid (2-isopropylmalic acid), a salt, hydrate or solvate thereof is administered at a dosage of 1.7 to 90 mg/kg/day. According to any one of claims 9 to 12,
The composition is a food composition composition. According to any one of claims 9 to 12,
Wherein the composition is a pharmaceutical composition. According to any one of claims 9 to 12,
The composition is a cosmetic composition composition.

Images